Biomarkers
AssigneesCambridge Enterprise Limited, Stichting VU
InventorsSabine Bahn, Emanuel Schwarz, Brenda Penninx, Nicole Vogelzangs
Life of this patent
Estimating the term…
Abstract
The invention relates to biomarkers and a method of diagnosing or monitoring depression, anxiety disorder or other psychotic disorder.
Claims21
1-21. (canceled)
A method comprising:
- (a) obtaining a biological sample from an individual and quantifying the amounts of biomarkers in the biological sample, wherein the biomarkers comprise at least two biomarkers selected from the group consisting of Interleukin 10 (IL-10), Interleukin 18 (IL-18), Interleukin 2 (IL-2), Interleukin 8 (IL-8), Monocyte Chemotactic Protein 1 (MCP-1), Macrophage Inflammatory Protein 1 alpha (MIP-1α), Macrophage Inflammatory Protein 1 beta (MIP-1β) Matrix Metalloproteinase 2 (MMP-2), Tumor Necrosis Factor beta (TNF-β), Interleukin 4 (IL-4), and Interferon gamma (IFN-γ);
- and
- (b) quantifying the amounts of the biomarkers in a control population to generate a reference standard wherein the control population comprises normal subjects;
- wherein the quantifying is performed by measuring the concentration of the analyte biomarkers by one or more methods selected from SELDI (-TOF), MALDI (-TOF), a 1-D gel-based analysis, a 2-D gel-based analysis, Mass spec (MS), reverse phase (RP) LC, size permeation (gel filtration), ion exchange, affinity, HPLC, UPLC or other LC or LC-MS-based technique, by an immunological method, or by a biosensor or a microanalytical, microengineered, microseparation or immunochromatography system.
A method comprising:
- (a) obtaining a biological sample from an individual and quantifying the amounts of biomarkers in the biological sample, wherein the biomarkers comprise at least two biomarkers selected from the group consisting of Interleukin 10 (IL-10), Interleukin 18 (IL-18), Interleukin 2 (IL-2), Interleukin 8 (IL-8), Monocyte Chemotactic Protein 1 (MCP-1), Macrophage Inflammatory Protein 1 alpha (MIP-1α), Macrophage Inflammatory Protein 1 beta (MIP-1β), Matrix Metalloproteinase 2 (MMP-2), Tumor Necrosis Factor beta (TNF-β), Interleukin 4 (IL-4), and Interferon gamma (IFN-γ);
- and
- (b) comparing the amounts of the biomarkers in the biological sample with the amounts of the biomarkers present in a reference standard.
A kit, comprising at least two ligands specific for at least two biomarkers selected from the group consisting of Interleukin 10 (IL-10), Interleukin 18 (IL-18), Interleukin 2 (IL-2), Interleukin 8 (IL-8), Monocyte Chemotactic Protein 1 (MCP-1), Macrophage Inflammatory Protein 1 alpha (MIP-1α), Macrophage Inflammatory Protein 1 beta (MIP-1β), Matrix Metalloproteinase 2 (MMP-2), Tumor Necrosis Factor beta (TNF-β), Interleukin 4 (IL-4), Interferon gamma (IFN-γ), Interleukin 6 (IL-6) and Tumor Necrosis Factor alpha (TNF-α).
Dependencies are inferred from the claim text.